Shares of Pfizer (NYSE: PFE ) hit a 52-week high on Wednesday. Let's take a look at how it got there and whether clear skies are still in the forecast.
How it got there
It's a little bit of a struggle to figure out how Pfizer has ascended to a new 52-week high considering that it lost patent protection on the best-selling drug in the world, Lipitor, and it's in the final stages of laying off an additional 16,300 employees in order to cut costs.
Including Lipitor, Pfizer is set to lose 23% of total fiscal 2011 sales over the next few years. With generic competitors Mylan (Nasdaq: MYL ) and Dr. Reddy's Laboratories (NYSE: RDY ) already producing significantly cheaper versions of Xalatan and Geodon, the company is scrambling for ways to replace drugs in its aging pipeline.
On the bright side, Pfizer continues to pay out an impressive dividend that yields nearly 4% and its forward P/E of just 10 would represent one of the lowest valuations in recent memory. Value investors looking for solid cash flow and a prime dividend continue to flock to Pfizer.
How it stacks up
Let's take a look at how Pfizer stacks up next to its peers.
Not surprisingly, the generic-drug producer Mylan is outperforming the large-scale pharmaceutical companies from which it pilfers its own generic pipeline.
|Merck (NYSE: MRK )||2.2||9.6||10.4||77%|
|GlaxoSmithKline (NYSE: GSK )||8.8||11.8||12.0||69%|
Sources: Morningstar and Yahoo! Finance. N/A = not applicable; Mylan doesn't pay a dividend.
Pfizer looks like the best buy on paper, but in reality I'd say it's far from it. It definitely has the most room to increase its dividend based on payout ratio alone, but it's contending with multiple drug expirations. GlaxoSmithKline is in the same boat as Pfizer with regards to patent expirations, but it has been eyeing acquisitions in India in an attempt to recapture some of its lost revenue. Merck, on the other hand, has been relatively unscathed. It's set to lose patent exclusivity on its blockbuster drug Singulair this year, but has a relatively healthy and safe pipeline beyond the loss. Finally, Mylan offers the most aggressive growth rates thanks to its generic portfolio, but it fails to pay its shareholders a dividend.
Now for the real question: What's next for Pfizer? That question really depends on whether Pfizer goes on the offensive and makes acquisitions, or ramps up its pipeline to replace the drugs set to fall off patent over the next few years. Based on Wall Street's revenue estimates, Pfizer could have some challenging times ahead.
Our very own CAPS community gives the company a four-star rating (out of five), with an overwhelming 90.3% of members expecting it to outperform. I am one of the few dissenters, having made a CAPScall of underperform on Pfizer, and am currently down seven points on that call. But, for those of you thinking I'm going to close this pick anytime soon...think again.
I called Pfizer the worst stock in the Dow Jones Industrial Average. Its erratic dividend, patent cliff woes, and rampant job cuts speak to the severity of Pfizer's internal problems. It doesn't help either that Pfizer's CEO, Ian Read, gave himself a hefty bonus in despite Pfizer's looming problems and job cuts. With revenue set to fall in each of the next two years according to Wall Street estimates, I have no problem with continuing to refer to this as the worst company of the Dow 30.
Craving more input on Pfizer? Start by adding it to your free and personalized Watchlist. It's a free service from The Motley Fool to keep you up to date on the stocks you care about most.